Optiver Holding
CRBP icon

Optiver Holding’s Corbus Pharmaceuticals CRBP Stock Holding History

Optiver Holding’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-929
Closed -$7.56K – 2402
2025
Q4 		$7.56K Buy
929
+917
+7,642% +$11.3K ﹤0.01% 1211
2025
Q3 		$152 Buy
+12
New +$114 ﹤0.01% 2587

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Optiver Holding's CRBP Position: Q1 2026 in Review

Optiver Holding sold out of Corbus Pharmaceuticals (CRBP) in Q1 2026, closing a stake of 929 shares — an estimated $7.56K sold.

Optiver Holding first reported a position in CRBP in Q3 2025 and held it in 2 quarters. The position peaked at $7.56K in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Optiver Holding reported no remaining Corbus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Optiver Holding sold 929 Corbus Pharmaceuticals shares in Q1 2026, an estimated $7.56K.
  • Optiver Holding first reported a position in Corbus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Optiver Holding's Corbus Pharmaceuticals position peaked at $7.56K in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.